Equities

Shanghai Serum Bio-Technology Co Ltd

688163:SHH

Shanghai Serum Bio-Technology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)15.20
  • Today's Change-6.04 / -28.44%
  • Shares traded1.36m
  • 1 Year change-29.20%
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Shanghai Serum Bio-Technology Co Ltd had net income fall -39.54% from 64.14m to 38.77m despite a 9.14% increase in revenues from 174.22m to 190.14m. An increase in the cost of goods sold as a percentage of sales from 19.23% to 26.21% was a component in the falling net income despite rising revenues.
Gross margin76.60%
Net profit margin25.81%
Operating margin31.11%
Return on assets4.48%
Return on equity4.62%
Return on investment4.56%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Shanghai Serum Bio-Technology Co Ltd fell by 364.81m. However, the company earned 32.82m from its operations for a Cash Flow Margin of 17.26%. In addition the company used 315.94m on investing activities and also paid 81.84m in financing cash flows.
Cash flow per share--
Price/Cash flow per share--
Book value per share10.30
Tangible book value per share10.08
More ▼

Balance sheet in CNYView more

Shanghai Serum Bio-Technology Co Ltd has little financial risk as the capital structure does not rely on leverage.
Current ratio44.41
Quick ratio42.72
Total debt/total equity0.004
Total debt/total capital0.004
More ▼

Growth rates in CNY

Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -73.33% and -39.54%, respectively. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
Div yield(5 year avg)--
Div growth rate (5 year)--
Payout ratio (TTM)42.50%
EPS growth(5 years)-1.62
EPS (TTM) vs
TTM 1 year ago
-2.37
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.